HRP20210398T1 - Režimi doziranja za liječenje pompeove bolesti - Google Patents
Režimi doziranja za liječenje pompeove bolesti Download PDFInfo
- Publication number
- HRP20210398T1 HRP20210398T1 HRP20210398TT HRP20210398T HRP20210398T1 HR P20210398 T1 HRP20210398 T1 HR P20210398T1 HR P20210398T T HRP20210398T T HR P20210398TT HR P20210398 T HRP20210398 T HR P20210398T HR P20210398 T1 HRP20210398 T1 HR P20210398T1
- Authority
- HR
- Croatia
- Prior art keywords
- dnj
- pharmaceutically acceptable
- acceptable salt
- replacement therapy
- human recombinant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261642311P | 2012-05-03 | 2012-05-03 | |
| US201261664011P | 2012-06-25 | 2012-06-25 | |
| US201261697179P | 2012-09-05 | 2012-09-05 | |
| US201361749234P | 2013-01-04 | 2013-01-04 | |
| US201361749132P | 2013-01-04 | 2013-01-04 | |
| PCT/US2013/039215 WO2013166249A1 (en) | 2012-05-03 | 2013-05-02 | Dosing regimens for the treatment of pompe disease |
| EP13785028.5A EP2844279B1 (en) | 2012-05-03 | 2013-05-02 | Dosing regimens for the treatment of pompe disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210398T1 true HRP20210398T1 (hr) | 2021-05-28 |
Family
ID=49514881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210398TT HRP20210398T1 (hr) | 2012-05-03 | 2013-05-02 | Režimi doziranja za liječenje pompeove bolesti |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20150086530A1 (enExample) |
| EP (3) | EP3871688B1 (enExample) |
| JP (6) | JP6381521B2 (enExample) |
| CY (1) | CY1124135T1 (enExample) |
| DK (1) | DK2844279T3 (enExample) |
| ES (2) | ES2859761T3 (enExample) |
| HR (1) | HRP20210398T1 (enExample) |
| HU (1) | HUE053565T2 (enExample) |
| LT (1) | LT2844279T (enExample) |
| PL (1) | PL2844279T3 (enExample) |
| PT (1) | PT2844279T (enExample) |
| RS (1) | RS61598B1 (enExample) |
| SI (1) | SI2844279T1 (enExample) |
| SM (1) | SMT202100136T1 (enExample) |
| WO (1) | WO2013166249A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12004868B2 (en) | 2011-06-03 | 2024-06-11 | Signpath Pharma Inc. | Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel |
| US10238602B2 (en) | 2011-06-03 | 2019-03-26 | Signpath Pharma, Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies |
| US10117881B2 (en) | 2011-06-03 | 2018-11-06 | Signpath Pharma, Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies |
| US8753674B2 (en) | 2011-06-03 | 2014-06-17 | Signpath Pharma Inc. | Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current |
| US10449193B2 (en) | 2011-06-03 | 2019-10-22 | Signpath Pharma Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies |
| US10349884B2 (en) | 2011-06-03 | 2019-07-16 | Sighpath Pharma Inc. | Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel |
| RS61598B1 (sr) * | 2012-05-03 | 2021-04-29 | Amicus Therapeutics Inc | Režimi doziranja za tretman pompeove bolesti |
| JP6895252B2 (ja) * | 2013-12-18 | 2021-06-30 | サインパス ファルマ, インク.Signpath Pharma, Inc. | 心筋ｉｋｒチャネルの薬剤誘発性阻害のリポソームによる軽減 |
| US9675627B2 (en) * | 2014-04-14 | 2017-06-13 | Amicus Therapeutics, Inc. | Dosing regimens for treating and/or preventing cerebral amyloidoses |
| EP3151837B1 (en) | 2014-06-03 | 2023-03-15 | Signpath Pharma, Inc. | Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies |
| JP6851964B2 (ja) | 2014-09-30 | 2021-03-31 | アミカス セラピューティックス インコーポレイテッド | 炭水化物が増大している非常に強力な酸性アルファ−グルコシダーゼ |
| ES3063549T3 (en) | 2015-12-30 | 2026-04-17 | Amicus Therapeutics Inc | Augmented acid alpha-glucosidase for the treatment of pompe disease |
| IL299470B2 (en) | 2015-12-30 | 2026-05-01 | Amicus Therapeutics Inc | Improved acid alpha-glucosidase for the treatment of Pompe disease |
| KR102618519B1 (ko) | 2016-03-30 | 2023-12-28 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 재조합 산 알파-글루코시다제를 포함하는 제형 |
| CA3019354A1 (en) | 2016-03-30 | 2017-10-05 | Amicus Therapeutics, Inc. | Method for selection of high m6p recombinant proteins |
| EP3448374B1 (en) | 2016-04-27 | 2025-02-12 | Signpath Pharma Inc. | Prevention of drug-induced atrio-ventricular block |
| WO2018209300A1 (en) * | 2017-05-12 | 2018-11-15 | Duke University | Methods for the use of low-dose immune modulators transiently for treating patients undergoing protein replacement therapy |
| CN119113091A (zh) * | 2017-05-15 | 2024-12-13 | 阿米库斯治疗学公司 | 重组人类酸性α-葡萄糖苷酶 |
| WO2022227287A1 (zh) * | 2021-04-25 | 2022-11-03 | 中南大学 | Dnj及其衍生物在制备预防和/或治疗肺动脉高压药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6534300B1 (en) | 1999-09-14 | 2003-03-18 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases |
| US20020095135A1 (en) | 2000-06-19 | 2002-07-18 | David Meeker | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| EP1436316B1 (en) | 2001-04-30 | 2008-01-23 | ZyStor Therapeutics , Inc. | Subcellular targeting of therapeutic proteins |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| US7658916B2 (en) | 2002-04-05 | 2010-02-09 | Genzyme Corporation | Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density |
| PT2332972T (pt) | 2003-06-24 | 2018-04-17 | Genzyme Corp | Novos promotores de beta-actina e rps21 e suas utilizações |
| US20080014188A1 (en) | 2004-02-06 | 2008-01-17 | Zankel Todd C | Manufacture of Highly Phosphorylated Lysosomal Enzymes and Uses Thereof |
| DE602005020745D1 (de) | 2004-02-10 | 2010-06-02 | Zystor Therapeutics Inc | Saure alpha-glukosidase und fragmente davon |
| EP3782655A1 (en) * | 2005-05-17 | 2021-02-24 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
| AU2008245578A1 (en) * | 2007-04-26 | 2008-11-06 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| WO2010056746A1 (en) * | 2008-11-11 | 2010-05-20 | Amicus Therapeutics, Inc. | Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease |
| RS61598B1 (sr) * | 2012-05-03 | 2021-04-29 | Amicus Therapeutics Inc | Režimi doziranja za tretman pompeove bolesti |
-
2013
- 2013-05-02 RS RS20210295A patent/RS61598B1/sr unknown
- 2013-05-02 SM SM20210136T patent/SMT202100136T1/it unknown
- 2013-05-02 JP JP2015510446A patent/JP6381521B2/ja active Active
- 2013-05-02 ES ES13785028T patent/ES2859761T3/es active Active
- 2013-05-02 PL PL13785028T patent/PL2844279T3/pl unknown
- 2013-05-02 HU HUE13785028A patent/HUE053565T2/hu unknown
- 2013-05-02 EP EP20207542.0A patent/EP3871688B1/en active Active
- 2013-05-02 US US14/398,210 patent/US20150086530A1/en active Pending
- 2013-05-02 ES ES20207542T patent/ES2980828T3/es active Active
- 2013-05-02 DK DK13785028.5T patent/DK2844279T3/da active
- 2013-05-02 SI SI201331858T patent/SI2844279T1/sl unknown
- 2013-05-02 EP EP13785028.5A patent/EP2844279B1/en active Active
- 2013-05-02 EP EP24161179.7A patent/EP4397364A3/en active Pending
- 2013-05-02 LT LTEP13785028.5T patent/LT2844279T/lt unknown
- 2013-05-02 HR HRP20210398TT patent/HRP20210398T1/hr unknown
- 2013-05-02 WO PCT/US2013/039215 patent/WO2013166249A1/en not_active Ceased
- 2013-05-02 PT PT137850285T patent/PT2844279T/pt unknown
-
2018
- 2018-01-19 JP JP2018007672A patent/JP6612370B2/ja active Active
-
2019
- 2019-10-29 JP JP2019196583A patent/JP6876111B2/ja active Active
-
2021
- 2021-01-27 JP JP2021010931A patent/JP7046241B2/ja active Active
- 2021-03-09 CY CY20211100202T patent/CY1124135T1/el unknown
-
2022
- 2022-03-22 JP JP2022044812A patent/JP2022101544A/ja not_active Withdrawn
-
2024
- 2024-03-07 JP JP2024034587A patent/JP2024081667A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP6381521B2 (ja) | 2018-08-29 |
| JP2020045346A (ja) | 2020-03-26 |
| LT2844279T (lt) | 2021-03-25 |
| SMT202100136T1 (it) | 2021-05-07 |
| JP2024081667A (ja) | 2024-06-18 |
| HUE053565T2 (hu) | 2021-07-28 |
| EP2844279A4 (en) | 2015-12-16 |
| EP4397364A3 (en) | 2024-09-04 |
| JP2021088561A (ja) | 2021-06-10 |
| SI2844279T1 (sl) | 2021-04-30 |
| JP2015519329A (ja) | 2015-07-09 |
| EP2844279A1 (en) | 2015-03-11 |
| CY1124135T1 (el) | 2022-05-27 |
| RS61598B1 (sr) | 2021-04-29 |
| JP2018109003A (ja) | 2018-07-12 |
| DK2844279T3 (da) | 2021-03-15 |
| EP3871688B1 (en) | 2024-03-06 |
| EP2844279B1 (en) | 2020-12-09 |
| JP6612370B2 (ja) | 2019-11-27 |
| JP6876111B2 (ja) | 2021-05-26 |
| PL2844279T3 (pl) | 2021-08-16 |
| JP7046241B2 (ja) | 2022-04-01 |
| WO2013166249A1 (en) | 2013-11-07 |
| ES2980828T3 (es) | 2024-10-03 |
| US20150086530A1 (en) | 2015-03-26 |
| PT2844279T (pt) | 2021-03-11 |
| JP2022101544A (ja) | 2022-07-06 |
| EP3871688A1 (en) | 2021-09-01 |
| ES2859761T3 (es) | 2021-10-04 |
| EP4397364A2 (en) | 2024-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124135T1 (el) | Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε | |
| JP2015519329A5 (enExample) | ||
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
| HRP20251310T1 (hr) | Enzimsko-nadomjesna terapija s povezivanjem doze za liječenje deficita kisele sfingomijelinaze | |
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| HRP20191162T1 (hr) | Postupci liječenja ankilozantnog spondilitisa uporabom anti-il-17 protutijela | |
| HRP20161038T1 (hr) | Genz 112638 za liječenje gaucherove ili fabrijeve bolesti u kombiniranoj terapiji | |
| BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| BRPI0508461B8 (pt) | diaminopirimidinas, seus usos, e composição farmacêutica | |
| BR112012020236A2 (pt) | uso de um composto com atividade antagonística de ep4 ou um sal farmaceuticamente aceitável do mesmo, uso de um composto da fórmula (i), (ii), (iii), (iv), (va) ou (vb), ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e método para o tratamento de doenças mediadas por il-23 em um sujeito animal, incluindo um sujeito mamífero | |
| JP2014528901A5 (enExample) | ||
| HRP20241454T1 (hr) | Migalastat za upotrebu u postupcima liječenja fabrijeve bolesti kod pacijenata koji imaju mutaciju u gla genu | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| AR082150A1 (es) | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio | |
| HRP20180468T1 (hr) | Novi derivat analoga inzulina | |
| BR112014003704A2 (pt) | moduladores ror gama | |
| JP2014513722A5 (enExample) | ||
| BR112014007357A2 (pt) | métodos de monitoramento terapêutico de fármacos de varredura de nitrogênio | |
| HRP20221366T1 (hr) | Postupci poboljšanja i/ili stabilizacije srčane funkcije kod bolesnika s fabrijevom bolešću | |
| HRP20240025T1 (hr) | Liječenje bolesnika s klasičnom fabrijevom bolešću migalastatom | |
| AR080096A1 (es) | Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib | |
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| HRP20192246T1 (hr) | Marker za poremećaje kisele sfingomijelinaze i njegova uporaba |